Versant Venture Capital VII, L.P. — SEC insider filings
SEC reporting owner CIK 1750266. 14 insider filings on record with FilingPulse; latest filed 2026-10-28.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2021-08-31 to 2026-10-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 40 legs across 10 filings — 3,735,262 shares, $94,503,339 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
- Largest priced transaction: sale of 350,000 shares @ $29.00 ($10,150,000) in LENZ Therapeutics, Inc., filed 2025-06-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | 10% owner | 9 | — | 34 legs · 1,885,262 sh · $66,603,139 | 1 |
| CHINOOK THERAPEUTICS, INC. (KDNY) | 10% owner | 3 | — | 6 legs · 1,850,000 sh · $27,900,200 | 5 |
| Lycia Therapeutics, Inc. (LYCA) | 10% owner | 2 | — | — | 4 |
Insider filings — Versant Venture Capital VII, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-28 | 4 | Lycia Therapeutics, Inc. (LYCA) jointly with Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Conversion (C): 5,631,425 · Conversion (C): 1,393,882 · Conversion (C): 25,390,410 (derivative) · Conversion (C): 6,284,597 (derivative) | EDGAR |
| 2026-10-22 | 3 | Lycia Therapeutics, Inc. (LYCA) jointly with Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC | Holdings only — no transactions reported | EDGAR |
| 2025-10-02 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 49,701 @ $45.35 · Sale (S): 34,405 @ $45.35 · Sale (S): 83,066 @ $46.41 · Sale (S): 57,502 @ $46.41 · Sale (S): 177 @ $47.01 · Sale (S): 123 @ $47.01 | EDGAR |
| 2025-09-22 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 49,479 @ $41.59 · Sale (S): 24,370 @ $41.59 · Sale (S): 40,907 @ $43.00 · Sale (S): 20,148 @ $43.00 · Sale (S): 268 @ $43.30 · Sale (S): 132 @ $43.30 | EDGAR |
| 2025-08-26 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 20,493 @ $40.03 · Sale (S): 10,076 @ $40.03 · Sale (S): 5,668 @ $40.59 · Sale (S): 2,809 @ $40.59 · Sale (S): 50,270 @ $39.53 · Sale (S): 24,760 @ $39.53 · +6 more | EDGAR |
| 2025-08-19 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 145,051 @ $39.50 · Sale (S): 69,949 @ $39.50 · Sale (S): 30,628 @ $38.56 · Sale (S): 15,085 @ $38.56 | EDGAR |
| 2025-07-14 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 191,376 @ $34 | EDGAR |
| 2025-07-01 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 200,000 @ $30.46 | EDGAR |
| 2025-06-20 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 100,000 @ $29.95 · Sale (S): 100,877 @ $30.35 · Sale (S): 133,924 @ $30.25 | EDGAR |
| 2025-06-12 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Sale (S): 350,000 @ $29 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC | Other (J): 598,203 | EDGAR |
| 2022-04-06 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) jointly with Versant Voyageurs I, L.P., Versant Voyageurs I Parallel, L.P. | Other (J): 709,953 @ $0 · Other (J): 14,194 @ $0 · Other (J): 14,194 @ $0 · Other (J): 11,726 @ $0 · Other (J): 11,726 @ $0 | EDGAR |
| 2022-01-05 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) jointly with Versant Voyageurs I, L.P., Versant Voyageurs I Parallel, L.P. | Sale (S): 600,000 @ $16.00 · Sale (S): 308,000 @ $16.00 · Sale (S): 92,000 @ $16.00 | EDGAR |
| 2021-08-31 | 4 | CHINOOK THERAPEUTICS, INC. (KDNY) jointly with Versant Voyageurs I, L.P., Versant Voyageurs I Parallel, L.P. | Sale (S): 510,000 @ $14 · Sale (S): 261,902 @ $14 · Sale (S): 78,098 @ $14 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-08-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1750266 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs